Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Non-Current Deffered Revenue (2020 - 2021)

Historic Non-Current Deffered Revenue for Oncology Institute (DFPH) over the last 2 years, with Q3 2021 value amounting to $6.3 million.

  • Oncology Institute's Non-Current Deffered Revenue changed 0.0% to $6.3 million in Q3 2021 from the same period last year, while for Sep 2021 it was $6.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $6.3 million for FY2020, which is N/A changed from last year.
  • As of Q3 2021, Oncology Institute's Non-Current Deffered Revenue stood at $6.3 million, which was down 0.0% from $6.3 million recorded in Q2 2021.
  • In the past 5 years, Oncology Institute's Non-Current Deffered Revenue ranged from a high of $6.3 million in Q1 2020 and a low of $6.3 million during Q1 2020